Mark Mulligan
Overview
Explore the profile of Mark Mulligan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Johnson J, Jones S, Wood S, Chaplin-Kramer R, Hawthorne P, Mulligan M, et al.
Ecol Appl
. 2019 Jul;
29(8):e01985.
PMID: 31348562
The Sustainable Development Goals (SDGs) emphasize the global and multi-dimensional nature of sustainability and thus require improving our capacity to articulate and trace the impact of ecosystem change to measures...
12.
Ferreira P, van Soesbergen A, Mulligan M, Freitas M, Vale M
Sci Total Environ
. 2019 Jun;
685:248-258.
PMID: 31176212
While the role of land-use conversion on water quality is reasonably understood, its role on water quantity is controversial. Climate change is also expected to impact water availability. Here we...
13.
Gunnell K, Mulligan M, Francis R, Hole D
Sci Total Environ
. 2019 Mar;
670:411-424.
PMID: 30909028
Cities are dependent on their upstream watersheds for storage and gradual release of water into river systems. These watersheds act as important flood mitigation infrastructure, providing an essential ecosystem service....
14.
Fisher B, Herrera D, Adams D, Fox H, Gallagher L, Gerkey D, et al.
Lancet Planet Health
. 2019 Mar;
3(3):e112-e113.
PMID: 30904104
No abstract available.
15.
Fong Y, Shen X, Ashley V, Deal A, Seaton K, Yu C, et al.
J Infect Dis
. 2018 Jan;
217(8):1280-1288.
PMID: 29325070
Background: HVTN 505 was a human immunodeficiency virus type 1 (HIV-1) preventive vaccine efficacy trial of a DNA/recombinant adenovirus serotype 5 (rAd5) vaccine regimen. We assessed antibody responses measured 1...
16.
Herrera D, Ellis A, Fisher B, Golden C, Johnson K, Mulligan M, et al.
Nat Commun
. 2017 Oct;
8(1):811.
PMID: 28993648
Diarrheal disease (DD) due to contaminated water is a major cause of child mortality globally. Forests and wetlands can provide ecosystem services that help maintain water quality. To understand the...
17.
Denjean B, Altamirano M, Graveline N, Giordano R, van der Keur P, Moncoulon D, et al.
Environ Res
. 2017 Aug;
159:24-38.
PMID: 28763731
This paper proposes a conceptual framework to systematize the use of Nature-based solutions (NBS) by integrating their resilience potential into Natural Assurance Scheme (NAS), focusing on insurance value as corner...
18.
Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker J, et al.
J Immunol
. 2017 Jun;
199(2):604-612.
PMID: 28607114
The incidence and severity of herpes zoster (HZ) increases with age. The live attenuated zoster vaccine generates immune responses similar to HZ. We compared the immune responses to zoster vaccine...
19.
Douglas C, Mulligan M, Harrison X, Henschel J, Pettorelli N, Cowlishaw G
PeerJ
. 2016 Nov;
4:e2622.
PMID: 27812420
Ephemeral rivers act as linear oases in drylands providing key resources to people and wildlife. However, not much is known about these rivers' sensitivities to human activities. We investigated the...
20.
Spearman P, Mulligan M, Anderson E, Shane A, Stephens K, Gibson T, et al.
Vaccine
. 2016 Oct;
34(46):5571-5578.
PMID: 27697302
Clinical Trials Registration: ClinicalTrials.gov NCT01169077.